These agents often carry a higher toxicity burden, usually manageablewith dose adjustments and supportive measures.84 In general, inhibitors ofATR-CHK1-WEE1 are characterized by hematological toxicity, with anemia moreprominent with ATR inhibitors and neutropenia with CHK1 and WEE1 inhibitors.However, safety data are still accumulating. This evidence concerns the gene CHEK1 and anemia.